Inspira Technologies OXY B.H.N. Ltd (NASDAQ:QTEX – Get Free Report) CEO Dagi Ben-Noon acquired 168,894 shares of the stock in a transaction dated Monday, September 28th. The stock was acquired at an average price of $0.71 per share, for a total transaction of $119,914.74. Following the completion of the transaction, the chief executive officer directly owned 3,646,133 shares of the company’s stock, valued at approximately $2,588,754.43. This represents a 4.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Inspira Technologies OXY B.H.N. Trading Up 15.0%
NASDAQ:QTEX opened at $0.78 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.00 and a quick ratio of 1.62. Inspira Technologies OXY B.H.N. Ltd has a 12-month low of $0.28 and a 12-month high of $3.85. The stock’s 50-day simple moving average is $0.88.
Inspira Technologies OXY B.H.N. (NASDAQ:QTEX – Get Free Report) last issued its earnings results on Thursday, September 24th. The company reported ($0.07) earnings per share (EPS) for the quarter. The company had revenue of $0.78 million during the quarter.
Analyst Ratings Changes
Several equities analysts have recently commented on QTEX shares. Weiss Ratings raised shares of Inspira Technologies OXY B.H.N. from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 25th. Wall Street Zen cut shares of Inspira Technologies OXY B.H.N. from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Inspira Technologies OXY B.H.N. currently has an average rating of “Sell”.
View Our Latest Stock Analysis on QTEX
Inspira Technologies OXY B.H.N. Company Profile
Inspira Technologies OXY B.H.N. Ltd. is an Israeli medical technology company focused on developing advanced respiratory-support systems for patients experiencing acute respiratory failure. The company’s technology is intended to support blood oxygenation and carbon-dioxide removal while potentially reducing reliance on invasive mechanical ventilation.
Its principal product platform is the INSPIRA ART system, an extracorporeal respiratory-support technology designed to oxygenate blood outside the body and return it to the patient.
Further Reading
- Five stocks we like better than Inspira Technologies OXY B.H.N.
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Appleās $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Inspira Technologies OXY B.H.N. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspira Technologies OXY B.H.N. and related companies with MarketBeat.com's FREE daily email newsletter.
